Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during ...

Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to ...

Please provide your email address to receive an email when new articles are posted on . Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy ...

An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment ...

For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has ...

The press release below was prepared by the American Association for Cancer Research. View the original here. Next-generation sequencing for minimal residual disease was highly sensitive and more ...

Correction to "Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow ...

Why minimal residual disease testing is the "gold standard" for some patients and providers. When Michael Ray went to his doctor for an annual checkup two years ago, he felt fine. But the bloodwork ...

Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome. However, the optimal time points for investigation, the best antibody ...